Latest news with #PercheronTherapeutics
News.com.au
31-07-2025
- Business
- News.com.au
Health Check: Today's flood of last-minute quarterly ‘homework' scores a solid pass
Plenty of biotechs are lodging late in the piece, but without too many 'dog ate my homework' excuses Telehealth group looks to post-pandemic recovery Botanix, Amplia and Vitrafy pass muster with the brokers Some students hand in their homework with days to spare, while others lob their hastily scrawled efforts at the eleventh hour. Plenty of biotechs also prefer the latter 'just in time' approach, judging from today's clump of quarterly reports lobbing in just ahead of today's end-of-month deadline. But in most cases, we won't mark down their quality. In the drug development domain, the 'students' are look well cashed up and well prepared. They've remembered to bring their excursion money and their sports uniforms. For instance, popular student Amplia (ASX:ATX) ended the quarter with cash of almost $6.7 million. This since has been bolstered by last week's $27.5 million capital raising. The company reported operating cash outflows of $3.8 million. This reflects spending on its 55-patient phase II pancreatic cancer trial, dubbed Accent. The study attracted wide interest by reporting 17 partial responses and two 'complete responses' – a.k.a. a cure. Given pancreatic cancer is such a deadly disease, this was most unexpected. Recovering from its failed Duchenne muscular dystrophy trial, Percheron Therapeutics (ASX:PER) spent just under $2.75 million, ending with cash of $10.16 million. This dosh is a lifeline for the company, which has acquired an immune-oncology drug asset. The developer of an ovarian cancer diagnostic and breast and lung cancer therapies, Inoviq (ASX:IIQ) expended a modest $1.44 million and ended up with cash of $6.5 million. Inoviq's chairman, the ubiquitous David Williams, attributes the company's sagging share price to a fund selling out. 'We anticipate share price recovery as the selling ends and we continue to advance our diagnostic programs,' he says. Medadvisor tempers expectations Following a weak June quarter related partly to cancelled US programs, medication compliance and drug education provider MedAdvisor (ASX:MDR) has tweaked its full-year guidance. Medadvisor now expects revenue for the year to June 2026 of $88 million, compared with the previously envisaged $93-99 million. Management expects an underlying loss of $6.5 to $7.3 million, compared with the previously guided $2.6 to $5.5 million. Medadvisor's June quarter revenue declined 16% to $18.6 million, with full year turnover declining 28%. The company cites several delayed US drug launch programs, which has deferred revenue into the current quarter. Medadvisor is aligned to the drug companies' rollout of new vaccines. But these have been stymied by sluggish demand amid the ongoing political controversy over these prophylactics. Meanwhile, the company has sold its non-core Australian ops to Jonas Software, for $35 million plus $7.5 million of earnouts. After extinguishing all its debt, Medadvisor has a healthy cash balance of $16.5 million. What's up DOC? A profit turnaround Doctor Care Anywhere Group PLC (ASX:DOC) slips under the radar because the telehealth provider operates solely in the UK. But we'll rectify this dearth of coverage by reporting that the company managed cash inflow of £2.17 million ($4.4 million) in the June (second) quarter. This is a turnaround from the March quarter deficit of £1.46 million and an 'historic milestone' for the company Receipts surged 32% to £10.93 million, despite consultations declining 7% year on year to 176,000. DOC ended the stanza with cash of £4.8 million ($10) million, 'enough to see the company through to long term profitability and continued net cash generation.' DOC works with insurers, healthcare providers and corporate customers to connect patients to digitally enabled telehealth services on its proprietary platform. The company listed here in December 2020, amid the pandemic-inspired telehealth craze, raising a chunky $101 million at 80c cents apiece. The shares have been in the sick ward ever since but achieving profitability would be the right prescription. Trio goes to the well Shares in Imagion Biosystems (ASX:IBX), Nyrada (ASX:NYR) and HeraMED (ASX:HMD) are on trading halt pending capital raising, with announcements expected on Monday. With $883,000 in the bank as of June-end, Imagion eyes more funds to further its innovative Magsense imaging system. The company is preparing a submission to the US Food & Drug Administration, for a trial enrolling HER-2 breast cancer patients. With cash of $2.93 million, Nyrada is seeking a top-up to support development of its drug candidate, Xolatryp, for traumatic brain injury and strokes. The company is undertaking a phase I TBI safety and efficacy trial. The developer of a foetal monitoring device, Heramed hasn't yet lodged its June quarterly. At the end of March, the company had cash of $1.88 million. Meanwhile oncology drug developer Prescient Therapeutics (ASX:PTX) said it had raised $3 million from a placement. This follows a share purchase plan that bought in $6.9 million. These readies should be enough to fund the company's phase II trial of its T cell lymphoma dug candidate towards 'potential regulatory approval'. What the brokers say Canaccord has initiated coverage on Botanix Pharmaceuticals (ASX:BOT) with a 'buy' call. This is despite taking a sterner stance on drug pricing, yields and script refill rates than the company's assumptions. Botanix in January launched the US rollout of its drug Sofdra, to treat the excessive underarm sweating condition primary auxiliary hyperhidrosis. Canaccord scribes a 'price target' of 27 cents per share, compared with Thursday' close of 17 cents. The firm assumes current year revenue of $67.8 million and a $41.8 million loss. Next year, turnover rises to $145 million, with a $14.3 million profit. Bell Potter reckons the aforementioned Amplia Therapeutics is worth almost twice as much as its current valuation, despite the drug developer's stellar run. The firm values Amplia shares at 42 cents, compared with 24 cents currently. Bel Potter also has a 'speculative buy' call on cryopreservation play Vitrafy Life Sciences (ASX:VFY). Vitrafy is developing its yet-to-be approved novel deep-freezing device, iiitally for the for research market. Vitrafy listed last November at $1.84 apiece, having raised $35 million. The firm values Vitrafy shares at $2, implying 22% of upside.
News.com.au
22-07-2025
- Health
- News.com.au
Dr Boreham's Crucible: After major setback, Percheron ploughs new direction
On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER) CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company's clinical development head Andrew McKenzie heard the grim tidings first and conveyed it to Garner that evening. 'I joked that I had been sitting on the couch, with a bottle of champagne on ice on one end and a bottle of whisky and revolver at the other,' Garner said. 'I said to Andrew 'what I am I drinking?' and he said: 'I hope it's good whisky'.' Testing Percheron's drug candidate ATL1102 (avicursen), the trial failed its primary endpoint based on upper limb performance of the non-ambulant subjects. 'My heart sunk,' Garner said. 'We spent the weekend picking through the data and it was just really clear it was as negative a result as they come.' The company immediately scrapped the program. After a bout of soul-searching Percheron hunted for another asset - and last month settled on an acquired immune-oncology program (see below). Along the way, the board stared down two spill attempts from aggrieved shareholders proposing alternative uses for Percheron's remaining cash kitty. Chance of success was '50-50' A regressive, fatal and poorly treated genetic disease, Duchenne muscular dystrophy (DMD) affects about one in 10,000 males (or 300,000 in all). DMD affects production of the muscle protein dystrophin, causing movement-related muscle damage leading to chronic inflammation and progressive loss of function. Garner says realistically the trial only had a 50% chance of success – the standard odds for a mid-staged program of its ilk. The nature of the endpoints also added another degree of difficulty, with a placebo effect creeping in. One example is measuring the patient's ability to drink a cup of water. 'If everyone is watching and wants you to succeed, you put that little bit more effort into it,' Garner says. And merely being on a study can make a patient feel better and improve behaviour. He says the patients were older boys who had been subject to other treatments – evidently with minimal success. As a result, carers and patients were realistic about the prospect of failure 'but it still hurts'. He says ATL1102 did show an effect – but it was not meaningful enough. From Toorak toff to draught horse Formerly known as Antisense Therapeutics, the company is an offshoot of Circadian Technologies and is one of the oldest ASX biotechnology companies. Quirkily, the company was based in Melbourne's upmarket Toorak, having sprung from Circadian Technologies. The company dabbled in multiple sclerosis, acromegaly and – later – Covid therapies. Having served as CEO for a record-breaking 17 years, Mark Diamond departed in May 2023 (he remains chairman of ASX listed kidney drug developer Dimerix). His replacement, Garner, is a qualified medical doctor. Garner worked at Biogen, Takeda and Sanofi, overseeing more than 30 product approvals and more than a dozen clinical trials, and was appointed CEO of the then ASX-listed brain cancer drug developer Kazia Therapeutics for seven years. Antisense licensed its key asset, ATL1102, from the Nasdaq-listed Ionis Pharmaceuticals (then Isis, but that lost popularity). Early last year, Antisense also changed its name – to Percheron – which means 'draught horse' in French. After the trial failure, a cabal of five shareholders requisitioned an extraordinary general meeting (EGM) to replace Garner and chair Dr Charmaine Gittleson and install three of its own board candidates. The resolution failed by a comfortable margin at the March 3 showdown. The ASX-listed Powerhouse Ventures had a crack along similar lines, but its proposal was defeated at an April 24 gunfight (by a wider margin). Percheron's new purpose On June 26, Percheron bought the exclusive rights to the HMBD-002 monoclonal antibody with potential applications in cancers, from Singapore's Hummingbird Bioscience. Percheron will pay Hummingbird an upfront US$3 million ($4.6 million), with contingent milestone payments of up to US$287 million ($443 million), plus royalties. Garner said the company has looked at more than 100 opportunities 'of every imaginable shape and size'. About half were oncology opportunities, with others including neurological and skin diseases including alopecia, irritable bowel disease and reverse takeovers. 'Some were cursory - we looked at them for an afternoon and decided this doesn't sound promising,' he says. 'With others we got into deep due diligence and spent weeks looking under the hood.' Familiar with Hummingbird's multi-faceted activities, Garner asked the company if it had anything interesting that didn't fit its strategy. And – voila! – HMBD-002 emerged from the bottom drawer. How it works HMBD-002 targets an agent called Vista, not a city view but a 'v-domain immunoglobulin suppressor of T-cell activation'. A new target 'Vista potentially represents a new mechanism to treat a diverse range of tumours.' As with other immuno-oncology drugs, HMBD-002 targets the interaction between the tumour and the immune system. (For a tumour to establish, it needs to dampen down the immune system or it gets attacked). Commercial treatments such as Yervoy and Keytruda are based on pathways such as programmed death-ligand 1 (PD-L1) inhibitors. ASX peer Immutep is tackling the Lag-3 pathway with encouraging results. 'There are nuanced differences, but they all basically work the same way,' Garner says. But Vista shows promise in overcoming strong patient resistance to the current drugs. 'For example, half to two-thirds of patients don't response to PD-L1 therapies,' Garner says. 'It may be that Vista stops them from responding.' This raises the prospects of a combination drug. Safety first HMBD-002 passed muster in a US-based 48-patient, phase I study, with 28 patients treated in combination with Keytruda. The trial showed the agent was 'pharmacologically active' and generally safe and well-tolerated. Another distinction is that most drugs to date have been based on the immunoglobulin 1 (IgG1) antibody that causes toxicity, cytokine release syndrome (CRS, inflammation from a hyperactive immune system). HMBD-002 harnesses the IgG4 antibody. 'While this sounds like a nerdy technical nuance, IgG4s don't cause CRS,' Garner says. The 28 patients dosed with Keytruda had no apparent CRS. 'Normally no one is excited about clearing phase I, but in oncology that's half the battle,' Garner says. 'If this had been presented to us as a pre-clinical opportunity, we would have been more wary.' Finances and performance In April, Percheron reported end of March quarter cash of $12.9 million. Accounting for the DMD trial wind-up costs and the acquisition, we estimate the June quarter statement will show cash of $5-$6 million. This dosh is the remnants of last year's $14.85 million capital raising, by way of an $8 million placement and a share purchase plan that bought in another $1.85 million, at eight cents a share (a 14% discount). Garner reckons these funds can go a long way, especially when combined with potential grants. 'Our priority is to get good convincing data, but often in oncology there are ways to do that, economically.' Should the company become profitable, it can avail of $82.4 million of accrued tax losses. Not surprisingly, Percheron's registry has evolved to largely retail holders, with most institutions 'gracefully' exiting after the Friday the 13th horror show. 'The register has been remarkably stable since ,' Garner says. 'For the most part, we have been left with a register of loyal shareholders who want the company to succeed.' Powerhouse Ventures is below the 5% threshold, while the five backers of the first coup attempt have shed their holdings altogether. Wisely, in April the company announced bonus loyalty options on a one-for-10 basis, exercisable at 3.5 cents within three years. Garner has forfeited half his salary, but – board note – he's never worked harder in his life to fix the snafu. In the meantime, ATL1102 remains on the books awaiting a divestment or partnership. 'It's probably not going to run off the shelves,' he says. 'We must find the right partner and the right circumstances.' 'But if we can give the drug a home and another chance then we would love to do that.' Percheron shares tumbled from six cents to one cent on the day of the trial news. The stock hit a 12-month peak of 12 cents in mid-October last year and an all-time high of 27 cents in October 2021. The company held a 10-for-one consolidation in 2013. The stock jumped 30%, or one-third of a cent on news of the asset purchase. Dr Boreham's diagnosis Garner says the company could have done little differently to ameliorate the risk of the DMD trial. For example, the 'imperfect' endpoints largely were determined by the regulators. 'The company had done all the reasonable things to take the risk out of it, but it was never a slam dunk,' Garner says. He says the acid test of any drug candidate is when it is applied in a large, randomised, multi-centre study. 'It's a reminder – if one is ever needed – that drug development is a risky business,' he says. 'Many drugs fail in development, through no fault of anyone. We set difficult tasks and sometimes don't succeed.' This is a lesson keenly felt by Opthea, which in March reported the failure of both of its phase III eye disease trials. While Opthea's fate is undecided, it is likely to be cruelled by the complex debt funding it had in place. Percheron is fortunate to be living another day, courtesy of its well-timed capital raising ahead of the Friday the 13th black-cat event. The Vista program is early stage, but promising. And, hopefully, management can banish the curse of avicursen. The crucial factor is that Percheron has acquired a genuinely promising asset, rather than 'this year's Christmas turkey' (as Garner puts it). Ultimately, he says, there's an element of gut feel in acquisitions. So, let's hope Percheron's corporate belly compass is pointing in the right direction. At a glance Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. He is relieved that no more Friday the 13ths are scheduled this year.
Associated Press
26-06-2025
- Business
- Associated Press
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Hummingbird Bioscience Media Contact: Crystal Ho [email protected] [email protected] +65 6979 5580 Hummingbird Bioscience Investor Contact: [email protected]
Business Upturn
26-06-2025
- Business
- Business Upturn
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
26-06-2025
- Business
- Yahoo
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact info@ CONTACT: Hummingbird Bioscience Media Contact: Crystal Ho media@ +65 6979 5580 Hummingbird Bioscience Investor Contact: investors@
